CLDX Live signals | Maximize Profits with Getagraph.com

BUY 157616 min ago

@ $36.11

Issued: 14 Feb 2024 @ 13:49

Return: -7.77%

Previous signal: Feb 13 - 12:40

Previous signal: Sell

Return: 0.46 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases...

Stats
Today's Volume	449 293
Average Volume	755 277
Market Cap	2.19B
EPS	$0 ( 2024-05-02 )
Next earnings date	( $-0.690 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.64
ATR14	$0.0380 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-13	Jimenez Freddy A.	Buy	20 000	Common Stock
2024-02-13	Jimenez Freddy A.	Buy	4 166	Common Stock
2024-02-13	Jimenez Freddy A.	Sell	4 166	Incentive Stock Option (Right to Buy)
2024-02-13	Jimenez Freddy A.	Sell	20 000	Incentive Stock Option (Right to Buy)
2024-01-02	Martin Samuel Bates	Buy	10 750	Common Stock

INSIDER POWER
75.90
Last 97 transactions
Buy: 2 900 849 \| Sell: 507 801

Volume Correlation

Long: 0.07 (neutral)

Short: 0.24 (neutral)

Signal:(54.218) Neutral

Celldex Therapeutics Inc Correlation

10 Most Positive Correlations
OZEM	1
FIMSX	0.877
ATGL	0.873
MAYHX	0.87
ATEX	0.858
RGSVX	0.848
INFR	0.847
RGIVX	0.847
IIXIX	0.845
FLOWX	0.84

10 Most Negative Correlations
PLTNU	-0.876
BOTT	-0.862
OPTZ	-0.858
AILEW	-0.851
MTEN	-0.831
COCH	-0.82
NWTN	-0.808
LDWY	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Celldex Therapeutics Inc Correlation - Currency/Commodity

-0.31
( neutral )

-0.25
( neutral )

0.00
( neutral )

-0.31
( neutral )

0.21
( neutral )

Celldex Therapeutics Inc Financials

Annual	2023
Revenue:	$6.88M
Gross Profit:	$3.88M (56.30 %)
EPS:	$-2.92

FY	2023
Revenue:	$6.88M
Gross Profit:	$3.88M (56.30 %)
EPS:	$-2.92

FY	2022
Revenue:	$2.36M
Gross Profit:	$957 000 (40.60 %)
EPS:	$-2.62

FY	2021
Revenue:	$4.65M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.640

Financial Reports:

No articles found.

Celldex Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.